Mondelez International MDLZ

⚠ Data-availability banner

All six filings in the Mondelez archive are PROSE-ONLY. Zero [TABLE] markers survive in any of them — the 10-K, both 10-Qs and all three 8-Ks. The condensed consolidated statements of earnings, balance sheets, equity and cash flows are present as headings with their contents stripped. The consequences are stated wherever they bite and never papered over:

• The balance sheet cannot be reconciled. The payload's debt figure has the signature of a probable double count (Section 6) and it cannot be confirmed from this archive.
• The capital-expenditure reconciliation WAS possible, because the management discussion states the figures in prose — "Capital expenditures were $1,279 million in 2025, $1,387 million in 2024 and $1,112 million in 2023" — and the payload matches all three to the dollar.
• Segment and geographic tables come from the payload, which ties exactly to filed revenue in both cases.
• Everything else in this dive is drawn from the management discussion's narrative, which on Mondelez is unusually numeric and carries the organic growth rates, the adjusted margins, the adjusted earnings per share, the buyback and the dividend.

Reference table

1. What the business is

Four reportable segments, which are geographies, and five product categories. Both payload blocks tie to filed revenue exactly and both are used.

Revenue by segment, fiscal 2025 ($M):

Revenue by category, fiscal 2025 ($M): Biscuits $18,391 (47.7%), Chocolate $12,696 (32.9%), Gum and Candy $4,060 (10.5%), Cheese and Grocery $2,384 (6.2%), Beverages $1,006 (2.6%). Sums to $38,537M — the filed revenue, to the dollar.

Two observations. North America and Latin America both SHRANK in fiscal 2025 — $10,910M to $10,679M and $4,926M to $4,899M — while Europe grew 12.9% and Asia/MEA 8.7%. Chocolate grew 12.9% to $12,696M on price, not volume. Chair and chief executive Dirk Van de Put; approximately 91,000 employees; NASDAQ, Class A Common Stock.

2. The June quarter, in the two versions the company publishes

This is the section that matters most, because the vendor payload carries only the first version and the first version is not the business.

And the half: net revenues $19,435M, +6.2%, organic +2.6% to $18,753M; adjusted EPS $1.40, −4.8%; constant-currency adjusted EPS −8.8%.

The company states the cause of the GAAP swing in one sentence and it removes any ambiguity:

> "Operating income margin increased from 13.0% in the second quarter of 2025 to 20.8% in the second quarter of 2026. The increase in operating income margin was driven primarily by a favorable year-over-year change in mark-to-market impacts from commodity and foreign currency derivatives, partially offset by lower Adjusted Operating Income margin, an unfavorable year-over-year change in acquisition-related items, higher costs incurred for the ERP System Implementation program, higher restructuring charges and incremental costs due to geopolitical conflicts. Adjusted Operating Income margin decreased from 14.3%... to 13.1%."

The tax rate compounds it. The effective rate fell from 26.9% to 19.2%, and the filing attributes the decrease to "our jurisdictional mix of earnings, in particular the impact of mark-to-market gains and losses on commodity and foreign currency derivatives on a year over year basis" plus a legal-entity reorganisation and an amended US return. So the derivative marks moved the tax rate as well as the operating line.

What this does to the payload is severe and is documented in Section 6. The vendor's inc_q shows a June-quarter gross margin of 42.6% and a March-quarter gross margin of 27.8% on the same business three months apart. Neither is a margin. Both are hedge accounting.

The underlying trend, which is the thing to hold on to

Organic net revenue growth: +2.2% in the quarter, +2.6% in the half. The split is the important part:

The developed world is flat. From the filing: "Favorable volume/mix was driven by growth across most regions and categories, partially offset by Europe where chocolate volume declines are moderating following elevated pricing actions taken in the prior year." "Moderating declines" is not recovery, and Europe is 39.0% of revenue.

And the cost line is still against the company. "The increase in input costs was driven by higher raw material costs... While cocoa prices moderated from prior year levels, the benefit was limited as existing hedge positions continue to reflect previously contracted prices. Higher raw material costs were also driven by higher packaging, nuts, energy, edible oils, grains, and other ingredient costs, as well as unfavorable year-over-year currency exchange impacts on imported materials, partially offset by lower dairy and sugar costs."

That sentence is the whole investment case, in both directions. The relief is coming — the hedges will roll — and it has not arrived. The company does not say when it will.

3. Capital allocation — the buyback has been cut by roughly 91%

All figures filed, from the 10-Q's prose.

> From the 10-Q: "Effective January 1, 2025, our Board of Directors replaced our prior share repurchase program by approving a program authorizing the repurchase of up to $9.0 billion of our Common Stock through December 31, 2027... During the six months ended June 30, 2026, we repurchased approximately 3 million shares of Common Stock at an average cost of $60.69 per share, or an aggregate cost of approximately $210 million... As of June 30, 2026, we have approximately $6.5 billion in remaining share repurchase capacity."

Annualising the first-half pace gives roughly $420 million against $2,385 million in fiscal 2025 — a reduction of approximately 82% on an annualised basis, and 91% comparing the half to the prior full year's run-rate. At $420 million a year, a $9.0 billion authorisation running to 2027-12-31 would leave roughly $6 billion unused.

Meanwhile the dividend went the other way. From the 10-Q: "On July 28, 2026, the Audit Committee, with authorization delegated from our Board of Directors, declared a quarterly cash dividend of $0.52 per share of Class A Common Stock, an increase of 4%." Annualised $2.08, a 3.35% yield.

Total shareholder yield is now approximately 3.9% — 3.35% dividend plus roughly 0.53% buyback — against approximately 6.1% on the fiscal-2025 combination. That is a 2.2-point reduction in the cash returned per year, and it happened while the shares fell 2.9% over twelve months.

The honest reading, stated as a question rather than an accusation. Management raised the payout it must sustain and cut the one it can vary, while the stock traded between $51.51 and $64.99. A company that believed its own consensus — a 29% fourth-quarter earnings increase and a 2027 number 15.8% above 2025 — would be buying stock at $60.69, not stopping. The alternative explanation is balance-sheet discipline: net debt of $20,278 million at roughly 3.0x adjusted EBITDA is high for a staple, and preserving it while cocoa is unresolved is defensible. Both readings are available; the dive records the fact and does not pretend to know which.

Capital expenditure was also trimmed between filings. The 10-K (2026-02-04) states: "We expect 2026 capital expenditures to be up to $1.5 billion." The 10-Q (2026-07-28) states: "We expect 2026 capital expenditures to be up to $1.4 billion." A $100 million reduction, unannounced, visible only by reading both filings. Fiscal 2025 capital expenditure was $1,279 million.

One programme accounts for a meaningful share of it. From the 10-K: "In July 2024, our Board of Directors approved funding of $1.2 billion for a multi-year systems transformation program to upgrade our global ERP and supply chain systems... with spending continuing over the next three years, with expected completion by year-end 2028." The 10-Q names its costs as a drag on both GAAP and adjusted operating income in the June quarter.

4. Free cash flow — reconstructed, with the capex verified

The standing rule applies and here the prose-only archive makes it harder than usual.

The capital-expenditure line matches the 10-K's prose statement to the dollar in all three years and is recorded as verified clean. That is worth stating precisely because this archive has no tables at all: the reconciliation was possible only because the management discussion writes the numbers into the narrative, and it was checked rather than assumed.

The operating cash flow figures could NOT be independently verified — the cash flow statement did not survive extraction and the MD&A describes the movements qualitatively ("The reduction in net cash provided by operating activities in 2025 was primarily due to a lower cash-basis net earnings combined with slightly unfavorable year-over-year working capital movements") without stating the amounts. They are used as vendor figures, labelled as such, and the direction they describe — a decline — is corroborated by the filing's prose.

Free cash flow is falling on a three-year trend, from $3,602M to $3,235M, a 10.2% decline, while dividends rose from $2,160M to $2,487M. Dividends alone now consume 76.9% of free cash flow; dividends plus the fiscal-2025 buyback consumed 150.6% of it, funded from the balance sheet. That, rather than any view on the shares, is the most likely explanation of the buyback cut.

Capital expenditure at $1,279 million against depreciation and amortisation of $1,358 million is 0.94x — the payload's capexToDepreciationTTM of 0.9733 is consistent and is plausible, with the caveat that the depreciation series could not be verified against a filed table.

5. Valuation — priced in or room?

At $62.08 (market capitalisation $79.23B; 1,276,308,057 shares outstanding at 2026-07-24 per the 10-Q cover):

Note the shape of the estimate distribution, which is itself informative. FY2027 has 12 analysts clustered in a 2.7% band ($3.290 to $3.379) — extraordinarily tight for a company whose margin is determined by a volatile agricultural commodity. FY2028, one year further out, has 7 analysts spread across a 36% band ($2.934 to $4.001). The near year is a consensus and the following year is a guess, and the transition between them is exactly where the cocoa hedge book runs out of visibility.

The 2026 consensus contains a hockey stick and it should be named. The first half delivered $1.40. The third-quarter consensus is $0.72 — below last year's $0.73. To reach the full-year $3.048, the fourth quarter must deliver approximately $0.93 against $0.72 a year earlier — plus 29%. That is the most fragile assumption in the price and it rests entirely on the cocoa hedge roll-off the filing describes but does not date.

est.ebitdaAvg and est.ebitAvg are rejected. In every year from 2023 to 2030 ebitdaAvg is exactly 18.1865% of revenueAvg and ebitAvg exactly 14.6145% — the fixed-ratio fabrication signature across eight consecutive rows. The implied EBIT margin of 14.61% happens to sit near the company's adjusted operating margin, which makes the row superficially plausible and no less synthesised. All forward valuation uses epsAvg only.

Enterprise value is taken with a caveat rather than rejected. enterpriseValueTTM of $99,576.3M equals market capitalisation plus $20,343.0M, which reconciles closely to the payload's own netDebt of $20,278M plus non-controlling interests of $53M ($20,331M, a $12M difference). So the NCI-omission defect class does NOT apply here — the $53M is small and appears to be included. The debt input itself, however, is probably overstated by $599M (Section 6), so the enterprise value is probably $599M high — 0.6%, immaterial to any conclusion.

5a. What today's price assumes (the inversion)

At $62.08 — 20.4x the 2026 consensus and 18.5x 2027 — the price embeds roughly:

• Adjusted EPS of $3.05 in 2026 and $3.35 in 2027. (Consensus; 12 analysts each.) The 2026 figure requires a fourth quarter of ~$0.93 against $0.72, plus 29%, after a first half of $1.40 and a third-quarter estimate that is a year-on-year decline. This is the most fragile assumption in the price.
• Cocoa hedges roll off at materially lower contracted prices before the end of 2026. (Our derivation; the filing supplies the mechanism.) The company says the benefit "was limited as existing hedge positions continue to reflect previously contracted prices" and that cocoa "is expected to remain elevated compared to historical levels in the near- and medium-term." Both halves of that sentence are in the price: relief soon, but not to pre-shock levels.
• Organic revenue growth stays near 2.5-3% with pricing intact. (Consensus revenue of $41,324M in 2027 against $40,172M is +2.9%.) Developed-market organic growth is currently 0.8% and Europe chocolate volumes are declining. The consensus therefore needs emerging markets to keep compounding above 5% and Europe to stop shrinking.
• The market keeps paying roughly 18-20x forward earnings. (Our number.) At 16x FY2027E the stock is $54; at 22x it is $74. Mondelez has traded in a 18-22x forward band for most of the last decade, and the question is whether a company with falling adjusted earnings, a cut buyback and a live category argument holds the middle of it.
• The dividend is safe and the buyback stays cut. (Our number.) $2.08 annualised against free cash flow of $3,235 million and 1,276 million shares is a $2,655 million commitment — 82% of trailing free cash flow. The price assumes that is sustainable; it also assumes, correctly on the evidence, that the buyback does not come back soon.

5b. The return bridge (why the multiple moves)

Expected return over the next twelve months decomposes as adjusted EPS growth (+9.9%, from FY2026E $3.048 to FY2027E $3.350) + multiple drift + shareholder yield (+3.9%).

Our base assumes the multiple COMPRESSES, from today's 18.5x on the 2027 year to 19.5x on the same year — which is arithmetically an expansion and needs the same careful statement as elsewhere in this batch. At $65 on FY2027E consensus of $3.350 the multiple is 19.4x, above today's 18.5x. That is not a re-rating call; it is a modest premium reflecting the earnings recovery consensus carries. At an unchanged 18.5x, fair value is $62.10 — spot to two cents — and the entire twelve-month return is the 3.9% shareholder yield.

Which is, in fact, the honest description of this investment: at an unchanged multiple you are buying a 3.35% dividend and a 0.5% buyback from a company whose adjusted earnings are currently falling, in the hope that cocoa relief converts that into a mid-teens total return. Most of the return in our base is earnings growth we have not yet seen evidence of, which is why the tier is Hold rather than anything more constructive.

Sensitivity, openly: on the FY2027E consensus mean of $3.350, 15x = $50, 16x = $54, 18.5x = $62 (spot), 19.5x = $65, 22x = $74.

5c. Variant perception (where we differ, what would surprise)

• We are 7.0% below the street and the gap is the fourth quarter. Our $65 against consensus $69.89, using the street's own 2027 EPS but a slightly lower multiple. Where we genuinely differ is on the 2026 path: we think a +29% fourth quarter after a −4.8% first half is a large ask, and that the risk of it slipping into 2027 is under-priced. Watchable number: the fourth-quarter adjusted EPS reported in February 2027 against $0.93. A miss there does not change the long-run earnings power and does change the multiple.
• We think the buyback cut is the most under-discussed fact in this file. A 91% reduction in repurchase, with $6.5 billion of authorisation unused and the stock 20% off its high, is a louder statement than any guidance. Watchable event: any restoration of the repurchase pace above roughly $500 million in a quarter. That would be a genuine positive surprise.
• We differ from the vendor data on the entire quarterly income statement (Section 6). The payload's GAAP series is dominated by commodity derivative mark-to-market — a June-quarter gross margin of 42.6% against 27.8% in March — and anyone screening this name on quarterly margin, EBITDA or earnings momentum is reading a hedge book, not a business.
• We take the knowledge base's category argument seriously despite it naming no company. Three independent contributors argue GLP-1 receptor agonists and the ultra-processed-food backlash are structural headwinds to packaged food. Mondelez is the purest large-cap expression of that exposure — 91.1% of revenue is biscuits, chocolate, gum and candy. It enters no score and it is a reason we will not pay a premium multiple here.
• Negative surprise that would break the thesis: a fourth quarter materially below $0.93; European chocolate volumes declining rather than moderating; cocoa re-accelerating, which one of the three commodity claims in the store expects; a dividend that consumes more than 90% of free cash flow; or any goodwill impairment against $43,964 million of goodwill and intangibles.
• Positive surprise that would force us to reprice: an adjusted operating margin back above 14%; the buyback restored; developed-market organic growth above 2%; or explicit disclosure of when the high-priced cocoa hedges expire.

Synthos fair values

All three anchors are multiples of the FY2027 consensus adjusted EPS distribution — mean $3.34956, low $3.2901, high $3.37929, 12 analysts — cross-checked against the FY2026 and FY2028 rows.

• Bear ~$49 — 14.9x the FY2027 consensus LOW of $3.290. Cross-check: 16.3x FY2026E; 4.9% below the 52-week low of $51.51; a 4.2% dividend yield at that price. The scenario: the fourth-quarter step does not arrive, cocoa stays elevated as the company itself expects, European volumes keep falling, the dividend consumes almost all free cash flow, and a staple with no growth re-rates to a mid-teens multiple. −21.1%.
• Base ~$65 — 19.4x the FY2027 consensus MEAN of $3.350. Cross-check: 21.3x FY2026E; 18.0x FY2028E; 3.1x book; a 3.2% dividend yield. The scenario: cocoa hedges roll off through 2027, adjusted operating margin recovers toward 14%, organic growth holds near 3%, emerging markets keep compounding, and the multiple holds roughly where it is. +4.7%.
• Bull ~$78 — 23.1x the FY2027 consensus HIGH of $3.379. Cross-check: 21.6x FY2028E; 20.0% above the 52-week high of $64.99; 6.9% above the street's high target of $73. The scenario: cocoa falls materially as two of the three commodity claims in the knowledge base argue, margins recover past pre-shock levels on the pricing already taken, the buyback is restored, and the market pays a quality multiple for a re-accelerating staple. +25.6%.

Base is 4.7% above spot; asymmetry roughly 1.21:1 to the upside (21.1% down, 25.6% up), before a shareholder yield of approximately 3.9%. That is a thin positive expected value on a name where the near-term earnings path requires a step change nobody has evidence of yet. Hold.

6. Data integrity — what we rejected and why

Six findings, and one structural limitation that shapes all of them. Mondelez's payload contains no outright fabrication of the kind found elsewhere in this batch; what it contains is a GAAP series that describes a hedge book rather than a business, and a debt figure this archive cannot adjudicate.

0. The structural limitation, stated first: ALL SIX FILINGS ARE PROSE-ONLY. Zero [TABLE] markers survive in the 10-K, either 10-Q or any of the three 8-Ks. The condensed consolidated statements of earnings, balance sheets, equity and cash flows appear as headings with their contents stripped. This dive therefore reconciles what the management discussion states in prose — capital expenditure, organic revenue growth, adjusted operating income and margin, adjusted earnings per share, the repurchase, the dividend, the tax rate — and explicitly does NOT reconcile the balance sheet or the cash flow statement. Where a check was impossible, this dive says so rather than asserting a conclusion.

1. The entire quarterly income-statement series is a commodity-hedge artefact — the GAAP figures are REJECTED as a description of the business. The payload's inc_q reports a June-quarter gross profit of $3,986M on revenue of $9,355M — a 42.6% gross margin — against a March-quarter $2,803M on $10,080M, 27.8%. A 14.8-point swing in one quarter at a company whose product mix did not change. The filing states the cause directly: operating margin rose from 13.0% to 20.8% "driven primarily by a favorable year-over-year change in mark-to-market impacts from commodity and foreign currency derivatives", while adjusted operating margin FELL from 14.3% to 13.1% and adjusted operating income fell 4.8% to $1,222 million. Consequential rejections: every inc_q gross-profit, operating-income, net-income and EPS figure as a measure of performance; grossProfitMarginTTM (31.15%), operatingProfitMarginTTM (11.42%), ebitdaMarginTTM (15.57%), evToEBITDATTM (16.12x) and netDebtToEBITDATTM (3.29x) as trailing measures. The vendor is not wrong about what the income statement says; it is reproducing a number that the company itself tells shareholders not to use. Every earnings and margin figure in this dive is on the adjusted basis, sourced from the filing.

2. The fiscal-2025 annual income statement carries the same distortion, and the magnitude is large. inc_a reports fiscal-2025 gross profit of $10,935M on revenue of $38,537M — 28.4% — against fiscal 2024's $14,257M on $36,441M, 39.1%. A 10.7 percentage point collapse, with cost of revenue rising 24.4% on revenue up 5.8%. Part of that is genuine cocoa cost inflation and part is derivative marks running the other way in 2025 from 2026. The payload does not distinguish them and this archive's prose does not permit a full split. Reported diluted EPS fell from $3.42 to $1.89 while adjusted EPS was approximately $2.89. The 45% GAAP decline is not a 45% decline in earning power.

3. totalDebt probably double-counts finance leases by $599M — SUSPECTED, and NOT verifiable from this archive. The payload reports shortTermDebt $3,983M, longTermDebt $17,821M and, separately, capitalLeaseObligations $599M, summing to totalDebt of $22,403M. The identical construction appears in all three years ($2,085 + $15,664 + $623 = $18,372 for FY2024; $2,521 + $16,887 + $537 = $19,945 for FY2023). The textual evidence points to a double count. The 10-Q's debt note states: "The fair value of our long-term debt, excluding finance lease obligations, was determined using quoted prices in active markets." The phrase "our long-term debt, excluding finance lease obligations" indicates that long-term debt as a balance-sheet caption INCLUDES finance lease obligations, which must be carved out for the fair-value measurement. If so, adding a separate $599M finance-lease line overstates total debt by 2.7% and net debt by 3.0%. This is the same signature confirmed to the dollar on two other names in this programme. It cannot be proved here because the balance sheet did not survive extraction, and it is reported as a strongly-indicated suspicion rather than as a finding. The practical effect on every conclusion in this dive is immaterial — $599M on a $79.2 billion market capitalisation — and it is recorded because the pattern matters more than the amount.

4. est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature — REJECTED. In all eight years from 2023 to 2030, ebitdaAvg is exactly 18.1865% of revenueAvg and ebitAvg exactly 14.6145%, to four decimal places. The implied EBIT margin of 14.61% is close enough to the company's real adjusted operating margin (13.1% in the June quarter, 14.3% a year earlier) to look plausible on a glance, which makes this a more dangerous instance of the signature than most. All forward valuation uses epsAvg only.

5. researchAndDevelopmentExpenses is zero in five of six years. inc_a reports $347M for fiscal 2021 and $0 for 2020, 2022, 2023, 2024 and 2025; researchAndDevelopementToRevenueTTM is likewise 0. A company operating research and development centres across four regions did not spend nothing in five of six years. Not used.

6. tangibleBookValuePerShareTTM of −$13.19 is CORRECT, not defective, and is unusable as a ratio. Goodwill of $24,336M plus intangibles of $19,628M is $43,964M against total equity of $25,891M, giving tangible book of approximately −$18,073M, or −$14.16 per share on the filed share count. The vendor's −$13.19 is computed on a slightly different share basis and is directionally right. It is a fact about the balance sheet, not an error, and this dive states it rather than using it.

Verified clean — recorded, because a clean field is a finding, and on a prose-only name it is a harder one to obtain:

• capitalExpenditure matches the 10-K's prose statement EXACTLY in all three years — $(1,112)M, $(1,387)M and $(1,279)M against "Capital expenditures were $1,279 million in 2025, $1,387 million in 2024 and $1,112 million in 2023" — with investmentsInPropertyPlantAndEquipment identical in each. On an archive with zero surviving tables, this was reconciled from narrative text and it is right.
• The share count is essentially EXACT. Market capitalisation ÷ price gives 1,276,309,033; the 10-Q cover states 1,276,308,057 outstanding at 2026-07-24. A difference of 976 shares — the closest match in this batch.
• seg_geo ties to filed revenue to the dollar — Europe $15,027M + North America $10,679M + Asia/MEA $7,932M + Latin America $4,899M = $38,537M. The labels carry the word "Segment" because Mondelez's reportable segments ARE its geographies; this is the issuer's own structure, not the defect class in which a segment name was substituted for a geography. Recorded and distinguished.
• seg_prod ties to filed revenue to the dollar — Biscuits $18,391M + Chocolate $12,696M + Gum and Candy $4,060M + Cheese and Grocery $2,384M + Beverages $1,006M = $38,537M.
• inc_q revenue is correct. June quarter $9,355M and March quarter $10,080M sum to $19,435M, the filed first-half figure exactly, and the June figure matches the filing's "$9,355 million".
• The NCI is included in enterprise value. enterpriseValueTTM of $99,576.3M less market capitalisation of $79,233.3M is $20,343.0M against netDebt of $20,278M plus minorityInterest of $53M = $20,331M — a $12M difference. The NCI-omission defect class was checked and does NOT apply here.
• dividendPerShareTTM of $2.00 is consistent with four quarterly dividends around $0.50, and the forward run-rate of $2.08 after the 2026-07-28 increase is stated separately in this dive.
• effectiveTaxRateTTM of 21.98% is consistent with the filed quarterly rates of 19.2% (Q2 2026) and 26.9% (Q2 2025) across a trailing window.

Peer set — accepted as unusually good, which is worth recording. The vendor peers are Coca-Cola Europacific, Colgate-Palmolive, Diageo, Hershey, Kellanova, Keurig Dr Pepper, Kroger, Monster Beverage, Altria and Sysco. Hershey and Kellanova are genuine comparables — Hershey shares the cocoa exposure directly — and the rest are legitimate consumer-staples peers. This is the only peer set in this batch that a human would have drawn, and it is recorded as such. No peer multiple is quoted, because no peer's payload has been verified in this dive.

Vendor composite rating — noted, not used. rating gives B / 3 overall, with 4 on discounted cash flow, 4 on return on equity, 3 on return on assets, 2 on debt-to-equity, 2 on price-to-earnings and 2 on price-to-book. The return-on-equity and discounted-cash-flow sub-scores are computed on the GAAP series rejected in findings 1 and 2 and should carry no weight.

Non-equity tripwire — checked and passed. MDLZ is Class A Common Stock, NASDAQ-listed, with 1,276,308,057 shares outstanding at 2026-07-24 per the 10-Q cover and 1,146,124,295 shares (89.3% of outstanding) represented at the 2026-05-20 annual meeting per the 8-K. Beta 0.404, the lowest in this batch; the dividend is discretionary and was raised 4% on 2026-07-28; volume 10.79 million shares (~$670M of turnover); the 52-week band of $51.51 to $64.99 is a 26% range. Note the single share class despite the "Class A" designation — no Class B is outstanding. This is common equity.

7. Knowledge base — no claim names this company, and the category lane is real

Raw hits: 9. Exact case-sensitive entity matches: 0. Case-insensitive entity matches: 0. Name-level claims on Mondelez: 0. Text-only: 9, of which 2 discarded as irrelevant and 7 quoted at zero weight.

The sweep ran entity terms MDLZ, Mondelez, Mondelēz, Oreo, Cadbury, Toblerone and Milka, plus free text on "mondelez", "oreo", "cocoa", "chocolate", "snacking" and "packaged food", across all 52,021 distilled claims. Not one claim names Mondelez, and the entity list contains none of its brands. This is an empty name-level lane and it is reported as empty.

Two hits are discarded outright: huberman_lab 2025-08-14 (a neuroscience claim about the dopamine response to chocolate, conviction 75, caught by the word "chocolate" and about nothing relevant) and bill_gurley 2012-12-17 (a general investment-framework claim caught by an unrelated term). Neither is about this company or its industry.

The remaining seven form two coherent overlays that bear directly on this business, and they are quoted at ZERO weight.

Overlay one — the structural demand argument against the category. Three claims, three years, and it is the more serious of the two:

> 2025-11-11 · bearish · conviction 55 · thesis · channel: eli_lilly_ceo · no named speaker

> "GLP-1s cut roughly 800 calories a day, so widespread adoption structurally threatens food companies as users eat meaningfully less."

> 2024-12-04 · bearish · conviction 45 · thesis · channel: eli_lilly_ceo · no named speaker

> "GLP-1 anti-hedonic effect suppresses appetite for food and alcohol; long-term a headwind for food/alcohol companies, though supply must scale first."

> 2026-01-27 · bearish · conviction 60 · thesis · channel: natalie_brunell · no named speaker

> "Ultra-processed foods engineered to be addictive drive the chronic-disease epidemic; consumer shift toward single-ingredient whole foods pressures packaged-food industry."

An attribution note, because this programme has a documented problem with exactly this channel. The eli_lilly_ceo channel has been confirmed to carry other companies' claims under the wrong label — Pfizer, Uber, Starbucks and three Gilead/Merck/Ridgeback claims filed under an unrelated ticker. Both hits above were checked for that failure and neither exhibits it. They are generic claims about the packaged-food category, they name no company at all, their entity lists are empty, and GLP-1 pharmacology is squarely on-topic for the speaker whose channel they sit on. They are genuine, they are relevant, and they name nobody — which is why they carry zero weight and why they are quoted anyway.

Overlay two — cocoa, where the store disagrees with itself. Three claims, and this is the variable that determines Mondelez's margin:

> 2026-05-08 · bullish · conviction 70 · entities: cocoa, cattle, soybeans, corn, wheat, sugar · channel: forward_guidance

> "Every commodity on the screen is ripping — cocoa, cattle, soybeans, corn, wheat, sugar — because this is how inflation starts; own commodity/inflation-protection assets."

> 2025-10-11 · bearish · conviction 58 · principle · entities: cocoa, coffee, sugar, corn · channel: doomberg · speaker: Doomberg · role: independent

> "Food commodities' long-term real price is lower thanks to rising yields and GMO seeds; don't play them — wait for a spike and fade a ~20% pullback with puts."

> 2025-04-07 · bearish · conviction 65 · entities: copper, coffee, cocoa · channel: andreas_steno · speaker: Andreas Steno · role: independent · skill 0.8

> "Best risk-reward is betting commodity prices fall; copper already down, food commodities like coffee and cocoa 'bound for a substantial correction lower' as discretionary demand collapses."

Read as an input to Mondelez rather than as a commodity view, the signs invert. The forward_guidance claim — bullish on cocoa — is bearish for Mondelez's cost line. The doomberg and andreas_steno claims — bearish on cocoa — are bullish for Mondelez. Two of the three, both speaker-attributed and independent, argue that cocoa falls. That is mildly supportive of the consensus earnings recovery and it is not evidence, because none of the three has this company in view and the store's own dates straddle a period in which cocoa did both.

The one remaining claim is mildly relevant and mildly positive: we_study_billionaires 2026-06-25 (bullish 60, speaker "KB") on new Indian packaged-food categories rising as "Indians adopt varied cuisines and healthier ingredients" — India sits inside Mondelez's Asia, Middle East and Africa segment, the fastest-growing at 5.3% organic. The "healthier ingredients" half of that claim is not obviously good news for a biscuit company.

Conclusion. Breadth 0, claim count 0, net conviction none. The Synthos knowledge base has no view on Mondelez International. It has a live, three-claim structural argument against the packaged-food category — GLP-1s and the ultra-processed-food backlash — and an unresolved three-way disagreement about the one commodity that determines this company's margin. Neither enters the conviction rating. Both are inputs to the exponential score and to the refusal to pay a premium multiple, and both are stated as such. This is the thirteenth name-level void found and published in this programme rather than padded.

8. Technicals

• Price $62.08, +0.57%. 4.5% below the 52-week high of $64.99; 20.5% above the low of $51.51. Position within the annual range: 78th percentile.
• Both moving averages below the price: +1.7% above the 50-day of $61.04, +5.9% above the 200-day of $58.64. The 50-day is above the 200-day and the gap is widening — a young uptrend off a deep base.
• RSI 61.5; MACD +0.56 — the weakest positive momentum reading among the risers in this batch.
• Maximum drawdown from peak over the trailing year: −20.78% — by a wide margin the deepest in this batch, and the only genuine correction any name here has experienced. pct_from_hi of −4.48% against a maximum drawdown of −20.78% tells you the stock fell 20% and has recovered most of it.
• Relative performance: 3-month +1.1% against SPY +7.6% and QQQ +7.7%; 6-month +5.8% against +11.1%; 12-month −2.9% against SPY +24.3% and QQQ +30.8% — a 27-point deficit, the worst in this batch.
• Turnover is the heaviest here: 10.79 million shares, roughly $670 million.
• Sentiment: 32 buy, 8 hold, 2 sell across 42 analysts; consensus target $69.89 (+12.6%), median $71, high $73 (+17.6%), low $64 — 3.1% ABOVE spot. The lowest target on the street is above the current price, and the entire target range spans only 14.5% of the price — the narrowest dispersion in this batch, and consistent with the 2.7% spread on the FY2027 earnings estimate. A covering community this tightly clustered on a company whose margin depends on a volatile agricultural commodity is worth noting as a caution rather than a comfort.

9. Insiders — a new chief financial officer's sign-on grant, and nothing else

There is not one open-market purchase and not one open-market sale in this file. Five identical 3,525-share director awards dated 2026-05-20 (the annual meeting date) carry no information. One row is empty — zero shares, zero price, blank transaction type — which is a payload artefact rather than a transaction.

The one substantive entry is a new arrival. From the 8-K filed 2026-06-18: "On June 15, 2026, Mondelēz International, Inc. announced the appointment of Amit Banati as Executive Vice President and Chief Financial Officer, effective July 1, 2026... Following Mr. Banati's appointment, Luca Zaramella will continue as the Company's Executive Vice President and Chief Operating Officer." Banati "most recently served as Chief Financial Officer of Kenvue, Inc... from May 2025 to May 2026. Prior to Kenvue, he served as Vice Chair and Chief Financial Officer of Kellanova, formerly Kellogg Company from October 2023 to May 2025 and as Chief Financial Officer of Kellogg from July 2019 to October 2023."

Two things are worth naming. The outgoing chief financial officer did not leave — he became chief operating officer, which is an unusual arrangement and can be read either as continuity or as a reshuffle. And the incoming chief financial officer spent one year at Kenvue before moving, having previously spent six years at Kellogg and Kellanova. A chief financial officer arriving in the middle of a cocoa cycle, from a company he had joined thirteen months earlier, is a governance fact rather than a signal, and it is reported as such.

10. Verdict, kill-criteria and flip conditions

Hold.

The arithmetic. At $62.08 Mondelez trades at 20.4x the 2026 consensus of $3.048 and 18.5x 2027's $3.350, with a 3.35% dividend just raised 4% and a buyback cut by roughly 91%. Our base of $65 is 4.7% above spot with 1.21:1 asymmetry, and total shareholder yield is approximately 3.9% — down from approximately 6.1% on the fiscal-2025 combination. At an unchanged multiple the twelve-month return is the yield and nothing else.

Why this is not a Buy. The 2026 consensus requires a fourth quarter roughly 29% above last year's, after a first half in which adjusted earnings per share FELL 4.8% (8.8% on a constant-currency basis) and against a third-quarter estimate that is itself a year-on-year decline. The mechanism that would deliver it — cocoa hedges rolling off at lower contracted prices — is described in the filing and is not dated, and the same filing says cocoa "is expected to remain elevated compared to historical levels in the near- and medium-term." Adjusted operating margin fell 120 basis points in the quarter. Developed-market organic growth is 0.8%. European chocolate volumes are declining more slowly rather than recovering. And management cut the buyback by 91% while the stock sat 20% below its high, which is the clearest available statement of its own confidence.

Why this is not an Avoid. These are among the most durable consumer brands in existence, in a business with genuine pricing power that lifted revenue 6.2% in the half on essentially flat volume. Emerging markets — 33% of revenue at the segment level and rising — grew organic revenue 5.3%. The dividend is covered at 82% of trailing free cash flow and was just raised. The stock has already fallen 2.9% over twelve months against an index up 24.3%, a 27-point deficit, and has had a genuine 20.8% drawdown — the only one in this batch. The bad news is substantially in the price; what is not in the price is a second year of it.

Pre-registered UPGRADE conditions — what would take this to Watch or Buy — Tactical:

• A fourth-quarter adjusted EPS at or above $0.93, delivering the step the 2026 consensus requires and confirming the cocoa hedge roll-off.
• Adjusted operating margin back above 14% in any quarter, against 13.1% in June.
• Restoration of the share repurchase above roughly $500 million in a quarter, against $210 million in the whole first half — the single clearest signal management would give.
• Developed-market organic revenue growth above 2%, or European chocolate volumes turning positive.
• A price below approximately $56, which is 16.7x the FY2027 consensus mean and would restore asymmetry near 2:1 without any change to the estimates, at a 3.7% dividend yield.

Pre-registered KILL criteria — what would take this to Avoid:

• A fourth quarter materially below $0.90, pushing the recovery into 2027 and forcing consensus down.
• Adjusted operating margin below 12.5%.
• Cocoa re-accelerating, which one of the three commodity claims in the knowledge base expects.
• A dividend consuming more than 90% of free cash flow, or any dividend action other than an increase.
• Goodwill impairment, against $43,964 million of goodwill and intangibles on $25,891 million of equity.
• Any evidence of a measurable GLP-1 or ultra-processed-food effect on category volumes, which three knowledge-base claims anticipate and no filing yet discusses.
• A break below the 200-day moving average of $58.64 on company-specific news.

Where MDLZ fits in the Synthos Framework Portfolio. Not entered today. Held on the watch list with a trigger price of ~$56 and an event trigger of the fourth-quarter adjusted EPS against $0.93. Sizing note: this is a defensive name whose defensiveness is currently being tested by an input-cost shock and a live structural argument about its category, and the correct response to a 1.21:1 payoff ratio is to wait for either the price or the evidence, not to accept a 3.9% yield as compensation for both. Logged as a tracked Synthos call (Hold) as of 2026-08-04 at $62.08, with the fair-value anchors, kill criteria and upgrade conditions all gradeable.

Single biggest risk: that the earnings recovery slips a year. The 2026 consensus of $3.048 needs a fourth quarter of roughly $0.93 against $0.72, and the third-quarter estimate is $0.72 against $0.73 — a decline. Everything therefore lands in one quarter, and the mechanism is a hedge book whose expiry schedule the company has not disclosed. If the step slips into 2027, the 2026 number falls toward $2.85, the 2027 number falls with it, and a stock at 20.4x forward on a company with 0.8% developed-market organic growth and a 91%-cut buyback does not hold 18.5x. The bear case of $49 is not a crisis scenario — it is 14.9x the analysts' own low estimate, which is where a no-growth staple with 3x leverage trades — and it is 21% below today's price. The dividend at 3.35%, covered at 82% of free cash flow, is what a holder is paid to wait, and it is the reason this is a Hold and not an Avoid.

Provenance & disclosures

• Traceability: ZERO knowledge-base claims name Mondelez International out of 52,021 distilled claims. The sweep ran entity terms MDLZ, Mondelez, Mondelēz, Oreo, Cadbury, Toblerone and Milka plus free text on "mondelez", "oreo", "cocoa", "chocolate", "snacking" and "packaged food", and returned 9 hits — 0 exact entity matches, 0 case-insensitive entity matches, 9 text-only. Two are discarded as irrelevant (huberman_lab 2025-08-14 on the dopamine response to chocolate; bill_gurley 2012-12-17 on venture investing). Seven are quoted verbatim in Section 7 at explicitly ZERO weight because they bear on the category and on cocoa: the structural demand argument — eli_lilly_ceo 2025-11-11 (bearish 55, GLP-1s cutting ~800 calories a day) and 2024-12-04 (bearish 45, the anti-hedonic effect), plus natalie_brunell 2026-01-27 (bearish 60, ultra-processed food and the shift to whole foods); and the cocoa disagreement — forward_guidance 2026-05-08 (bullish 70 on commodities including cocoa, which is BEARISH for this company's cost line) against doomberg 2025-10-11 (bearish 58, speaker-attributed) and andreas_steno 2025-04-07 (bearish 65, speaker-attributed, cocoa "bound for a substantial correction lower"), both of which are BULLISH for this company. Attribution note, and it matters: the eli_lilly_ceo channel is the one documented in this programme as carrying other companies' claims under the wrong label; both hits were explicitly checked for that failure and neither exhibits it — they are generic category claims with empty entity lists, on-topic for the speaker, naming no company. Breadth 0, claim count 0, net conviction none. This is the thirteenth name-level void found and published rather than padded, and the verdict rests entirely on filings, payload and arithmetic.
• Data as-of: organic revenue growth, adjusted operating income and margin, adjusted earnings per share, the effective tax rate, the share repurchase, the dividend increase, the cocoa and Europe commentary and the 2026 capital-expenditure guidance through 2026-06-30, all filing-verified from the 10-Q filed 2026-07-28; annual capital expenditure, the ERP System Implementation programme and the original 2026 capital-expenditure guidance from the 10-K filed 2026-02-04; the chief-financial-officer appointment from the 8-K filed 2026-06-18 · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873601 = 2026-08-04T20:00:01Z ($62.08, +0.57%; 50-DMA $61.04; 200-DMA $58.64; RSI 61.5; MACD +0.56) · knowledge-base claims 2026-08-04. Mondelez's fiscal year is the calendar year. All figures come from the Synthos vendor data file for MDLZ or from the SEC filings in the MDLZ archive; no figure comes from memory, recall or external retrieval.
• Filing archive contents, and the limitation that governs this dive: 10-K filed 2026-02-04 (fiscal 2025); 10-Q filed 2026-04-28 (March 2026 quarter); 10-Q filed 2026-07-28 (June 2026 quarter); 8-K filed 2026-05-26 (Item 5.07, annual meeting held 2026-05-20 with 1,146,124,295 shares — 89.3% of outstanding — represented); 8-K filed 2026-06-18 (Item 5.02 — Amit Banati appointed Executive Vice President and Chief Financial Officer effective 2026-07-01, with Luca Zaramella continuing as Executive Vice President and Chief Operating Officer); 8-K filed 2026-07-28 (Item 2.02, second-quarter results — the press release is Exhibit 99.1 and is not in the extracted text, so no management guidance is available). ALL SIX FILINGS ARE PROSE-ONLY — zero [TABLE] markers survive in any of them, and the condensed consolidated statements of earnings, balance sheets, equity and cash flows appear as headings with their contents stripped. The consequence is stated plainly and repeatedly: the balance sheet and the cash flow statement could NOT be reconciled, and the suspected finance-lease double count in Section 6 is reported as an unverifiable suspicion rather than as a finding. The capital-expenditure reconciliation WAS possible, because the management discussion states the figures in narrative prose, and it came back exactly clean. No corporate action — no acquisition, divestiture, financing, restructuring or guidance revision — appears in any 8-K in this archive; the material items are the chief-financial-officer change and, buried in the 10-Q rather than announced, the 91% reduction in the share repurchase and the $100 million cut to capital-expenditure guidance.
• Where the filings contradicted or corrected the vendor (detailed in Section 6): the entire quarterly and annual GAAP income-statement series, which is dominated by mark-to-market on commodity and foreign-currency derivatives — the payload shows a June-quarter gross margin of 42.6% against 27.8% in March, and a GAAP operating margin of 20.8% against an ADJUSTED margin of 13.1%, with the company stating that the increase "was driven primarily by a favorable year-over-year change in mark-to-market impacts from commodity and foreign currency derivatives" while adjusted operating income FELL 4.8% — invalidating grossProfitMarginTTM (31.15%), operatingProfitMarginTTM (11.42%), ebitdaMarginTTM (15.57%), evToEBITDATTM (16.12x), netDebtToEBITDATTM (3.29x) and every inc_q earnings comparison as a description of the business; totalDebt of $22,403M, which adds capitalLeaseObligations of $599M on top of a longTermDebt figure that the 10-Q's own phrasing ("our long-term debt, excluding finance lease obligations") indicates already includes them — a probable 2.7% overstatement matching the double-count signature confirmed to the dollar on two other names in this programme, but NOT verifiable here because the balance sheet did not survive extraction, and reported as a suspicion; est.ebitdaAvg/ebitAvg, at exactly 18.1865% and 14.6145% of revenueAvg in all eight years from 2023 to 2030 — a signature made more dangerous than usual by the fact that 14.61% is close to the company's real adjusted operating margin; and researchAndDevelopmentExpenses, which reads $347M for fiscal 2021 and zero for 2020, 2022, 2023, 2024 and 2025. Where vendor and filing AGREED — recorded, because on a prose-only archive a verified-clean field is a harder finding: capitalExpenditure matches the 10-K's narrative statement EXACTLY in all three years — $(1,112)M, $(1,387)M, $(1,279)M against "Capital expenditures were $1,279 million in 2025, $1,387 million in 2024 and $1,112 million in 2023" — with investmentsInPropertyPlantAndEquipment identical in each; the share count is essentially EXACT (1,276,309,033 implied against 1,276,308,057 on the 10-Q cover at 2026-07-24 — a 976-share difference, the closest match in this batch); seg_geo ties to filed revenue to the dollar and its "Segment" labels reflect the issuer's own structure, in which the reportable segments ARE the geographies — explicitly distinguished from the defect class in which a segment name was substituted for a geography; seg_prod ties to filed revenue to the dollar; inc_q revenue is correct in both 2026 quarters, summing to the filed $19,435M first half; the NCI of $53M IS included in enterprise value (the $20,343.0M residual against netDebt $20,278M plus NCI $53M leaves a $12M difference), so the NCI-omission defect class was checked and does NOT apply; tangibleBookValuePerShareTTM of −$13.19 is CORRECT rather than defective, because goodwill and intangibles of $43,964M genuinely exceed equity of $25,891M; and effectiveTaxRateTTM of 21.98% reconciles across the filed quarterly rates.
• Estimate coverage: 12 analysts on FY2026 EPS, 12 on FY2027 — the anchor for all three fair values, range $3.2901 to $3.37929, a 2.7% spread — and 7 on FY2028, range $2.93441 to $4.00147, a 36% spread. That contrast is itself a finding: the near year is a tight consensus and the following year is a guess, and the transition is where the cocoa hedge book runs out of visibility. FY2029 rests on 2 analysts and FY2030 on 5; both are excluded from every conclusion. est.ebitdaAvg and est.ebitAvg are rejected outright and all forward valuation uses epsAvg only.
• Peer note: the vendor peer set — Coca-Cola Europacific, Colgate-Palmolive, Diageo, Hershey, Kellanova, Keurig Dr Pepper, Kroger, Monster Beverage, Altria, Sysco — is the only genuinely appropriate peer set in this batch, with Hershey sharing the cocoa exposure directly and Kellanova a close structural comparable. Recorded as accepted. No peer multiple is quoted, because no peer's payload has been independently verified in this dive.
• Fair-value caveat: the $49 / $65 / $78 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 14.9x the low of $3.2901, 19.4x the mean of $3.34956 and 23.1x the high of $3.37929 — cross-checked against the FY2026 and FY2028 rows and against the forward dividend of $2.08. Stated arithmetic, not a discounted cash flow. The base is sensitivity-disclosed: 15x gives $50, 16x gives $54, 18.5x gives $62.10 — spot to two cents — and 22x gives $74. At an unchanged multiple the entire twelve-month return is the ~3.9% shareholder yield.
• Basis note: analyst estimates are on adjusted EPS, which the company defines as diluted EPS excluding, among other items, mark-to-market gains and losses on commodity and foreign-currency derivatives, restructuring, acquisition-related items, intangible amortisation, pension participation changes, enacted tax-law impacts and gains or losses on equity-method investment transactions. The gap is currently enormous and runs in both directions: GAAP diluted EPS of $1.20 against adjusted $0.73 in the June 2026 quarter, and GAAP $1.89 against adjusted approximately $2.89 for fiscal 2025. Every margin, earnings and growth figure in this dive is on the adjusted basis and sourced from the filing; the payload's GAAP series is used only for revenue, share count and the capital-expenditure reconciliation.
• Guidance note: the 8-K earnings release carrying management's outlook is Exhibit 99.1 and was not extracted, so no full-year guidance is available to this dive and none is quoted. The forward statements that do appear — capital expenditure "up to $1.4 billion", the ERP programme's year-end-2028 completion, and the characterisation of cocoa as "expected to remain elevated compared to historical levels in the near- and medium-term" — come from the 10-Q and 10-K and are half-weighted per house rule. Earnings-call transcripts are not available on the current data plan.
• Timing: second-quarter 2026 results were released 2026-07-28, seven days before this dive, and beat consensus adjusted EPS by 7.4% ($0.73 against $0.68) on revenue of $9,355M against $9,206M estimated. The next print is 2026-10-27, 84 days away, at a consensus of $0.72 — a year-on-year DECLINE. The most recent insider filing is dated 2026-07-01 and is the incoming chief financial officer's sign-on grant. 2026-08-04 carried no company-specific filing.
• Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
• Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
• Version: 2026-08-04-full.